Background: Cannabis is the most commonly consumed illicit drug around the world; in Germany, about 4.5% of all adults use it each year. Intense cannabis use is associated with health risks. Evidence-based treatments are available for health problems caused by cannabis use.
ecreational use of cannabis has recently been legalized in several states of the USA. At the same time, scientific research is improving our knowledge of the therapeutic potential of medicinal drugs containing cannabis (1) . In this light, it is not surprising that more and more patients are asking their doctors and other healthcare professionals for information about the health risks and medical benefits of cannabis.
Cannabis is the most widely consumed illegal substance across the world (2) . According to United Nations estimates, 125 to 227 million people consume cannabis worldwide (2) . A recent national epidemiological survey of addiction in Germany showed that 4.5% of the adult population had used cannabis in the previous year (3) . Consumption is particularly common among 18-to 20-year-olds (12-month prevalence: 16.2% ). An estimated 1% of the population of the European Union (12 million persons) are daily users of cannabis (4) . Cannabis is mostly consumed in the form of marijuana (dried flowers and leaves) or hashish (the delta-9-tetrahydrocannabinol [THC]-containing resin of the inflorescences) (4) . Oil containing THC is also sometimes ingested in foodstuffs. Police reports indicate that cannabis plants are increasingly being grown in European countries and less cannabis is being imported (4) .
The content of THC, the principal psychotropic substance in cannabis, has increased sharply in the past decade (4) . Another active ingredient, cannabidiol (CBD), is no longer present in many strains (e1, e2). The anxiolytic, antipsychotic, anti-inflammatory, antiemetic, and neuroprotective actions that are ascribed to CBD (e3) may compensate the adverse effects of THC (5) . The consumption of cannabis products high in THC and low in CBD is thought to cause undesired effects in persons with a corresponding predisposition (e4) . The total number of addiction treatments owing to cannabis consumption is increasing in Europe and the USA (2, 4, e5) .
Further cannabinoid-associated disorders are defined in and in . While ICD-10 distinguishes between harmful and addictive use of cannabis, in DSM-5 the severity of health impairment can be classified in three segments (mild, moderate, severe) of a continuum. Both classifications also describe a specific cannabis withdrawal syndrome, which can occur within 24 h of consumption (10, 11, e8, e9) . For cannabis withdrawal syndrome to be diagnosed, at least two mental symptoms (e.g., irritability, restlessness, anxiety, depression, aggressiveness, loss of appetite, sleep disturbances) and at least one vegetative symptom (e.g., pain, shivering, sweating, elevated body temperature, chills) must be present. The symptoms are at their most intensive in the first week and can persist for as long as a month. Clinically, withdrawal from cannabis is usually uncomplicated (10, 11, e10, e11) .
In the German general population, around 1% of adults fulfill the DSM-IV criteria of cannabis abuse (0.5%) or cannabis addiction (0.5%) (3) . For comparison, higher rates of prevalence are found for alcohol abuse and dependence (3.1% and 3.4% respectively) and for nicotine addiction (10.8%) (3) . Dependence on other illegal substances, e.g., amphetamines (0.2%) or cocaine (0.3%) is less common (3) . Overall, around 9% of all cannabis consumers become dependent on cannabis at some time during their lives (e12). This rate rises to 17% for those who started using cannabis in adolescence (e13) and 25 to 50% if cannabinoids are consumed daily (e14) . As yet there are no data for Germany on the prevalence of health impairments as a result of cannabis use according to The amotivational syndrome, characterized by reduced motivation to perform the activities of daily living, disorders of concentration and attention, and blunting of affect (e15), has been insufficiently investigated to date and empirical proof is lacking (e16) . In regular consumers of cannabis this pattern of symptoms may be produced by a disturbance of focused attention (e17) or a prolonged intoxication effect (12) .
Cognitive consequences
A meta-analysis (13) (evidence level: 1a) reported mild negative effects on learning capacity (effect strength [ES] = -0.24, 99% confidence interval [CI] -0.39 to -0.02) and memory (ES = -0.27, 99% CI -0.49 to -0.04) in non-abstinent habitual consumers of cannabis. These effects were also demonstrable after at least 24 h abstinence. Attentiveness and reaction time were not impaired. A more recent meta-analysis (14) (evidence level: 1a) also shows low-level global cognitive impairments in acute cannabis consumption (global ES = -0.29, 95% CI -0.46 to -0.12). Compared with abstinent persons, non-abstinent cannabis users exhibited mild impairments in the following areas:
• Abstract thinking or executive performance (ES = -0.21, 95% CI -0.38 to -0.05)
• Attention (ES = -0.36, 95% CI -0.56 to -0. 16 (18), cohort study (e31) (evidence level: 2b); in cannabis users (N = 270) daily cannabis consumption predicted more rapid progression of hepatic fibrosis (>0.15) (OR = 3.6; 95% CI: 1.5-7.5).
Case series (e32), review of these case reports (e33) (evidence level: 4) Reviews (19, 20) , case reports, reviews of the cases (e.g., e34, e35; evidence level: 4) Case reports (e36, e37), case-control study: increased risk of MI up to 60 min after cannabis consumption (OR = 4.8; 95% CI: 2.4-9.5) (e38) (evidence level: 1b); part of prospective study (e39) In women: adverse effects on frequency of menstrual cycle, oogenesis ("maturation of oocytes"), implantation of embryo, development of brain in embryo, increased risk of birth complications, decreased birth weight of child In children of women exposed to cannabis during pregnancy: increased impulsiveness, impairment of learning, memory, and executive functions, particularly following exposure in the third trimester In men: ejaculation problems, decreased sperm count, libido loss or impotence Tumor diseases Nasopharyngeal tumors (independent of tobacco consumption) (18), cohort study (e48) (evidence level: 2b): cannabis smoke is carcinogenic and cannabis use can cause tumors of the upper respiratory tract, the GIT, the lungs, and the bladder; cohort case-control study (e48): n = 75 patients and n = 319 controls; cannabis consumption (even at a high level) was not associated with an increased risk of head and neck tumors (after adjusting for potential confounding variables) (evidence level: 2b).
Basic science-oriented review without statistical analysis (26) (evidence level: 4)
Somatic risks
The Table provides an overview of the possible somatic consequences of acute and chronic use of cannabis.
Mental comorbidity
Affective disorders, suicidality, anxiety disorders: Between 50% and 90% of cannabis-dependent persons are diagnosed with a further mental disorder or health impairment from consumption of alcohol or other substances at some point in their lives (e49) . Some studies suggest a positive relationship between cannabis consumption and bipolar disorders (27, 28, e50-e52) or between augmented manic symptoms and cannabis use (e52, e53) . (31) , and no consistent causal link has been found (31, 32, e56, e57) . Chronic intoxication, withdrawal symptoms, additional addictions, adaptational or personality disorders, and-particularly in adolescents-disorders of emotional development and social behavior are assumed to be further additional factors in the development of depression and suicidality in cannabis users (30, 33, e54, e58) . In bipolar disorders, above all, accompanying cannabis use is associated with a less favorable course, poorer adherence, elevated risk of suicide, and decreased response to lithium (e59) . Treatment of the affective disorder may lead to reduction of the accompanying cannabis use (34) . Treatment of the cannabis dependency is also probably advantageous for the course of the affective disorder. To date this assumption is based exclusively on clinical observation, with no empirical support. More evidence exists for a connection between cannabis use and anxiety disorders, particularly panic disorders. The risk of an anxiety disorder was significantly elevated in persons who consumed cannabis weekly up to the age of 29 years (OR 3.2, 95% CI 1.1 to 9.2) (e60) (evidence level: 2b). Furthermore, epidemiological investigations have revealed a 2.5-to 6-fold risk of anxiety disorders in those dependent on cannabis (e61).
Psychoses: Early, regular, long-term, and heavy consumption of cannabis, in association with other stressors such as experience of violence and abuse in childhood or psychoses in the original family, has been connected with increased risk of psychotic disorders (30, 35, e62-e64) . The pooled data in a meta-analysis quantified the increased risk of psychoses after frequent cannabis consumption with an OR of 2.09 (95% CI 1.54 to 2.84) (evidence level: 2a). In the presence of a
• Learning (ES = -0.35, 95% CI -0.55 to -0.15) • Psychomotor functions (ES = -0.34, 95% CI -0.57 to -0.11) After abstinence for at least a month, these differences were no longer detectable (ES = -0.12, 95% CI -0.32 to 0.07). The effects may be reversible in adults. Other studies show that especially in consumers who began using cannabis in adolescence, cognitive impairments may still be present after 4 weeks' abstinence. Persisting mild to moderate deficits were found in the following areas: A long-term study in New Zealand yields evidence of an unfavorable influence of regular cannabis consumption in adolescence on intelligence in later life (e20) (evidence level: 1b). In persons who had regularly used cannabis before reaching the age of majority, the mean intelligence quotient at the age of 38 years was eight points lower than at the age of 13 years. These effects were not evident in probands whose long-term consumption of cannabis had begun when they were already adult. The study excluded any possibility that the effects were due to acute cannabis intoxication, addiction to other substances, schizophrenia, or a lower level of education. These findings indicate elevated vulnerability to neurocognitive impairments among adolescents who regularly use cannabis, with questionable reversibility (e21) (evidence level: 2a).
These results are complementary to age-dependent structural changes in the gray and white matter of the brain. In a study of young cannabis users (e22), the decrease in volume of the right amygdala and the hippocampus on both sides of the brain correlated with the severity of dependence on cannabis (R 2 = 0.54) and the amount of cannabis consumed weekly (R 2 = 0.43). There is also evidence of changes in the axonal fiber pathways (e23) (evidence level: 1b): cannabis users showed a loss of axonal integrity (reduction of fiber pathways by up to 84%) in the area of the right fimbria and bilaterally in a region of the corpus callosum, as well as a decrease of 88% in the fiber bundle from the splenium of the corpus callosum to the right precuneus. In both cases the age at which regular cannabis use had begun correlated significantly with radial (t = 2.5, p = 0.02 versus t = 4.0, p = 0.002) and axial (t = 1.9, p = 0.06 versus t = 3.2, p = 0.002) density.
Influence on education
A meta-analysis of three prospective cohort studies with a total of over 6000 participants suggests a connection between early cannabis use (before the age of 15 years) and an increased risk of leaving school early or attaining a lower level of education (15) (36) (37) (38) .
Consumption of cannabis and other substances:
Various studies have demonstrated a link between early, regular cannabis use and continuing consumption of other illegal drugs or alcohol (33) . However, there are no empirical data to support the gateway hypothesis, i.e., the notion that use of cannabis leads directly to use of other substances (e65, e66) . Secondary cannabis consumption: Many consumers may use cannabis to alleviate troublesome psychic or physical symptoms (e67). This has been reported for patients with posttraumatic stress syndrome (e68, e69) or chronic pain (e70). Cannabis is also smoked by some persons with schizophrenic psychoses, perhaps because of the antipsychotic action of CBD (e3), and increases the risk of more and longerlasting paranoid syndromes (e71) and intoxication phenomena (e72, e73) in 40% of user.
Further research is required to clarify the causal nature of the links between cannabis consumption patterns and adverse events. In future studies particular care should be taken to control for confounding variables.
Treatment
In Europe, cannabis consumption is the most common reason for a first drug treatment due to use of an illegal substance (4) . The number of first treatments rose from 45 000 to 61 000 between 2006 and 2011 and remained stable at 59 000 in 2012.
In Germany, patients with cannabis-related disorders are usually treated as outpatients, e.g., in dependency outreach services, addiction clinics, or specialist centers. Uncomplicated withdrawal is also treated on an outpatient basis.
Qualified inpatient treatment is indicated in the case of:
• Complicated course of intoxication • Severe withdrawal syndrome and/or severe aftereffects • High danger of relapse • Comorbid mental disorders (39) The treatment is divided into acute and post-acute phases. The acute phase (duration 2 to 4 weeks; in adolescents, 4 to 12 weeks) can include physical detoxication, diagnosis, and treatment of withdrawal symptoms, as well as detection and possibly treatment of any coexisting disorders. In addition to intensive counseling and structuring of daily activities, accompanied by psychopharmaceutical support if indicated, the patient is encouraged to begin abstinencestabilizing treatment in cases where treatment motivation is lacking in the presence of impairment of psychosocial function (i.e., difficulties in organizing the daily routine and structuring activities).
More complicated episodes of intoxication may be characterized by panic attacks or by psychotic or delirious symptoms. In these cases it is helpful to talk to the patient and, if applicable, to administer antipsychotics (preferably atypical) and/or sedatives for a limited period of time (39) .
Rehabilitational postacute treatment (duration: 6 to 9 months) serves to ensure abstinence, prevent relapse, stabilize the patient's mental, social, and occupational situation, and treat any comorbidity. In adolescents, attention needs to be paid to educational support, reintegration into school, and the situation regarding family and residence.
Psychotherapeutic interventions
A meta-analysis (40) and several systematic reviews of RCTs (evidence level: 1a) (e74-e76) demonstrate that short interventions (6 to 12 sessions) with combinations of measures to promote motivation, cognitivebehavioral therapy, and contingency management (learning via systematic rewards) have the greatest effect. Furthermore, family therapy interventions have proved effective in children and adolescents (evidence level: 1a) (e74). The abstinence rates lie between 10 and 50% (40, e77-e81) . Around half these patients relapse within a year (40, e77-e81) .
More successful than the attempt to achieve abstinence from cannabis are measures to reduce the frequency and intensity of consumption and ameliorate the psychosocial problems and other health impairments associated with cannabis use (e75) .
Internet-and computer-based interventions are effective in reaching young people at the time when their use of cannabis is becoming problematic and in achieving a reduction in consumption (e82).
Pharmacotherapy
No medications are yet licensed for the treatment of cannabis-related disorders. Drug treatment is necessary only in the presence of severe withdrawal symptoms (e.g., with gabapentin, benzodiazepines, sedative antipsychotics), psychoses (with antipsychotics), or panic attacks (with benzodiazepines, sedative antipsychotics) (39) . Two RCTs investigated treatment of cannabis withdrawal with synthetic THC (dronabinol) or cannabis extracts (e.g., nabiximols). These medications were superior to placebo with regard to compliance and amelioration of withdrawal symptoms, but not for reduction of consumption (e83, e84) .
Buspirone and the CB1-receptor antagonist rimonabant have also been shown to be effective (e85); however, rimonabant was taken off the market in 2008 because of its depressive action.
Summary
The use of cannabis is widespread, extending from experimental consumption to dependence. Empirical data have now clearly shown that starting early in life and regularly using high amounts of cannabis for a long period of time increases the risk of various mental and physical disorders and endangers age-appropriate development. Because many studies have failed to control properly for confounding variables, it still cannot be stated beyond doubt that there is a causal connection between cannabis consumption patterns and cognitive damage or the development of comorbid psychic or somatic disorders. The worldwide increase in the THC content of cannabis may increase the health risks, particularly for adolescent users. Further research is required to determine why some people are more affected than others by the unfavorable consequences. 
KEY MESSAGES
• Cannabis is the most frequently consumed illegal drug in Germany and the most common reason for a first drug treatment.
• Nine percent of all cannabis users, 17% of those who begin using cannabis in adolescence, and 25 to 50% of persons who consume cannabis daily become dependent.
• Starting in adolescence and high-dose, long-term, and regular use of cannabis increase the risk of various disorders of mental and physical health and endanger age-appropriate development. Other specific risk factors are currently being investigated.
• The worldwide continuing increase in the content of delta-9-tetrahydrocannabinol (THC) -the principal psychoactive ingredient-in cannabis products may be associated with greater risks to health, particularly for adolescent users.
• Combinations of measures to increase motivation, cognitive-behavioral therapy, and contingency management (specific rewards), together with family therapy interventions in adolescents, are currently the most effective approaches to the treatment of cannabis dependency.
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